KBC Group
ZYNE

KBC Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

KBC Group’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-650
Closed -$6K – 1419
2018
Q2 		$6K Hold
650
– – ﹤0.01% 1284
2018
Q1 		$6K Buy
+650
New +$7.01K ﹤0.01% 1272

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KBC Group's ZYNE Position: Q3 2018 in Review

KBC Group sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2018, closing a stake of 650 shares — an estimated $6K sold.

KBC Group first reported a position in ZYNE in Q1 2018 and held it in 2 quarters. The position peaked at $6K in Q2 2018. 66 funds tracked by Wall St. Rank hold ZYNE as of Q3 2018.

  • KBC Group reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2018 after selling out during the quarter.
  • KBC Group sold 650 Zynerba Pharmaceuticals, Inc shares in Q3 2018, an estimated $6K.
  • KBC Group first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2018 and held it in 2 quarters.
  • KBC Group's Zynerba Pharmaceuticals, Inc position peaked at $6K in Q2 2018.
  • 66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2018.

Based on KBC Group's 13F filing for Q3 2018, filed 14 Nov 2018.